Conditions: Malignant Pleural Effusion
Keywords: Bevacizumab; non-small cell lung cancer; malignant pleural effusion; intrapleural administration
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 72
Healthy volunteers: no

Brief summary:
To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).

Detailed description:

Arms:
arm 1: Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks arm 2: Cisplatin 30mg by intrapleural given every two weeks

Interventions: intervention 1: Bevacizumab intervention 2: Cisplatin
Intervention descriptions: intervention 1: Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week intervention 2: Cisplatin 30mg,intrapleural administration,each 2 week

Protocol document: